Laky, Brenda and Janda, Monika and Kondalsamy-Chennakesavan, Srinivas and Cleghorn, Geoffrey and Obermair, Andreas (2010) Pretreatment malnutrition and quality of life - association with prolonged length of hospital stay among patients with gynecological cancer: A cohort study. BMC Cancer, 10(1). pp. 232-237.

© 2010 Laky et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pretreatment malnutrition and quality of life - association with prolonged length of hospital stay among patients with gynecological cancer: a cohort study.

Brenda Laky\textsuperscript{1,4*}, Monika Janda\textsuperscript{2*}, Srinivas Kondalsamy-Chennakesavan\textsuperscript{4*}, Geoffrey Cleghorn\textsuperscript{3,4*}, Andreas Obermair\textsuperscript{1,4*§}.

\textsuperscript{1}Queensland Centre for Gynaecological Cancer, The Royal Brisbane and Women's Hospital, Level 6 Ned Hanlon Building, Herston Queensland 4029, Australia.
\textsuperscript{2}Queensland University of Technology, School of Public Health, Brisbane, Australia
\textsuperscript{3}Children's Nutrition Research Centre, Royal Children's Hospital, Brisbane, Australia
\textsuperscript{4}University of Queensland, School of Medicine, Brisbane, Australia

*These authors contributed equally to this work
§Corresponding author

Email addresses:
BL: brendalaky@yahoo.de
MJ: m.janda@qut.edu.au
SK: uqskonda@uq.edu.au
GC: g.cleghorn@uq.edu.au
AO: andreas_obermair@health.qld.gov.au
Abstract

Background
Length of hospital stay (LOS) is a surrogate marker for patients’ well-being during hospital treatment and is associated with health care costs. Identifying pretreatment factors associated with LOS in surgical patients may enable early intervention in order to reduce postoperative LOS.

Methods
This cohort study enrolled 157 patients with suspected or proven gynecological cancer at a tertiary cancer centre (2004-2006). Before commencing treatment, the scored Patient Generated - Subjective Global Assessment (PG-SGA) measuring nutritional status and the Functional Assessment of Cancer Therapy-General (FACT-G) scale measuring quality of life (QOL) were completed. Clinical and demographic patient characteristics were prospectively obtained. Patients were grouped into those with prolonged LOS if their hospital stay was greater than the median LOS and those with average or below average LOS.

Results
In univariate models prolonged LOS was associated with low serum albumin or hemoglobin, malnutrition (PG-SGA score and PG-SGA group B or C), low pretreatment FACT-G score, the occurrence of surgical adverse events and diagnosis of cancer. In multivariable models adjusted for pretreatment clinical diagnosis, PG-SGA group B or C, FACT-G score independently predicted LOS.

Conclusions
Malnutrition, low quality of life scores and being diagnosed with advanced ovarian cancer are the major determinants of LOS amongst gynecological cancer patients. Interventions addressing malnutrition and poor QOL may decrease LOS in gynecological cancer patients.
Background
Despite significant advances in cancer therapy, in-patient hospital care remains a major expense in the treatment of patients with gynecological cancer. Reducing length of hospital stay (LOS) has the potential to reduce health care cost, risk of infections and other hospital acquired diseases, and to improve patients’ quality of life (QOL). Previous studies have observed differential LOS by cancer type and stage, however, these characteristics commonly are not available before surgery, and thus are not amenable to pre-treatment interventions. Identifying modifiable risk factors at admission predicting (LOS) could lead to appropriately targeted interventions to improve the delivery of care for women with gynecological cancer. Previous research has shown that preoperative serum albumin (a marker of chronic malnutrition), hemoglobin and lymphocyte status are associated with LOS and mortality in the gynecological oncology setting [1-4]. Preoperative medical conditions or co-morbidities could also be associated with LOS; however findings regarding these predictors are inconsistent [4, 5].

Acute malnutrition may be a further potentially amenable risk factor for LOS. Malnutrition has been found to be associated with increased risk of morbidity and mortality, complication rates such as wound infections, costs of hospitalisation, and decreased QOL in various cancer populations [2, 4, 6-16]. The scored Patient Generated - Subjective Global Assessment (PG-SGA) is a validated nutritional assessment tool specifically designed for cancer patients. Using the PG-SGA, we have observed high levels of nutritional deficiencies among patients with gynecological cancer, especially those diagnosed with ovarian cancer [17, 18], but to date no study has assessed whether the scored PG-SGA can predict prolonged LOS among gynecological cancer patients.

Gynecological cancer and/or malnutrition can have a profound impact on patients’ physical function and psychosocial well-being – both important components of QOL. One common
definition of QOL is that it is a subjective, multidimensional construct representing functional status, mental and social well-being as well as general health [19]. Health-related QOL before treatment commences has been suggested as an important prognostic factor in ovarian cancer patients [20, 21]. To our knowledge, no study to date evaluated the association between preoperative QOL, malnutrition and LOS among a wider range of gynecological cancer patients.

Thus, the purpose of this study was to evaluate factors available prior to initial treatment to predict LOS in patients with suspected or proven gynecological cancer and to assess their independent contribution once post-treatment (histology, stage and adverse events) information was considered.

**Methods**

The study was conducted at the Queensland Centre for Gynecological Cancer at the Royal Brisbane and Women’s Hospital, Brisbane, Australia. Patients with presumed or proven primary gynecological cancer were screened for eligibility at their preoperative visit between March 2004 and December 2006. Patients were excluded from the study if they presented with recurrent cancer, had received treatment for other cancers within the past five years, had psychological or cognitive impairments (e.g. schizophrenia, dementia) or were non-English speaking. A total of 194 patients gave informed written consent. Thirty-two study participants declined to complete the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire and five participants had to be excluded from analyses due to incomplete data. Overall, 157 women completed both the scored PG-SGA and the FACT-G questionnaire before commencing treatment. Patients’ clinical and demographic characteristics including age at study entry, body mass index, serum albumin, hemoglobin, lymphocytes, co-morbidities, adverse events, surgical approach, LOS, and histopathological diagnosis and
staging according to the International Federation of Gynecology and Obstetrics (FIGO) were recorded prospectively. Six women did not undergo surgery, because a surgical approach was contraindicated or chemotherapy and/or radiotherapy was initiated as the primary treatment. Pre-treatment serum albumin levels were recorded in 146 patients; hemoglobin and lymphocyte count in 153 patients and actual body weight and height for all but one patient. All pre-treatment predictive factors were collected either at the outpatient or preadmission clinic, typically one to five weeks before primary treatment was initiated. The median waiting time for surgery was two weeks for ovarian and cervical cancers and five weeks for endometrial cancer and women with suspected benign diseases, respectively. Women were categorised according to their clinical diagnosis before surgery: pelvic mass, or suspected advanced ovarian cancer, cervical cancer or endometrial cancer. This study has been approved by The Royal Brisbane and Women’s Hospital Human Research Ethics Committee (Protocol Number 2004/007) and the University of Queensland Medical Research Ethics Committee (Brisbane, Australia; Project Number 2006000533).

Nutritional assessment

The scored PG-SGA is a validated nutritional assessment tool for cancer patients [9, 16] that records and summarizes weight changes, alterations in food intake, gastrointestinal symptoms (such as nausea, vomiting and diarrhoea that have persisted for two weeks), and changes in functional capacity and physical signs of malnutrition. These signs were assessed by a trained clinical dietician using skinfold measurements (loss of subcutaneous fat, muscle wasting, edema). The presence of ascites was established radiologically and abstracted from the clinical notes for this study. Based on the global rating, women were classified as well nourished (PG-SGA A); moderately malnourished or suspected of being malnourished (PG-SGA B); or severely malnourished (PG-SGA C). The PG-SGA also incorporates a numerical
score (PG-SGA score). Typical scores achieved by gynaecological cancer patients range from 0-28 [22], with higher scores reflecting greater risk of malnutrition. Scores of nine or more indicate a critical need for nutritional intervention options and/or improved symptom management [23].

**QOL assessment**

QOL was measured by the FACT-G questionnaire, which is a widely utilized and validated instrument [24]. Version 4 of the FACT-G is a 27-item self-report measure and allows patients to rate their current physical (7 items, range: 0-28), social and family (7 items, range: 0-28), emotional (6 items, range: 0-24), and functional well-being (7 items, range: 0-28). The FACT-G is scored using a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). The raw scores were are linearly transformed as per questionnaire manual with higher scores indicating better QOL [25].

**Statistical analysis**

Descriptive statistics were used to summarize patient characteristics and to group patients by the main outcome variable (average versus prolonged LOS). Prolonged LOS was defined as LOS of greater than five days for patients who underwent open abdominal surgery and greater than two days for patients who underwent vaginal or laparoscopic surgery. Univariate logistic regression analyses were conducted to calculate odds ratios adjusted for age and surgical approach for patients who had prolonged compared to average LOS. Variables significantly associated with LOS were then entered into a multivariable model (Table 1).
All models described above were adjusted for age and surgical approach (open-abdominal, vaginal or laparoscopic surgery). Hosmer-Lemeshow goodness-of-fit statistic assessed fit of the models. SPSS software version 16.0 Graduate Student (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses.

Results

Patient Characteristics
Patients’ mean age was 58 years (SD 14 years). Preoperatively, 81 (52%) patients presented with a pelvic mass, 23 (15%) were suspected to have advanced ovarian cancer, 36 (23%) patients to have endometrial cancer, and 17 (11%) patients to have cervical cancer. Ninety-four patients were operated using an open-abdominal, 40 patients with a laparoscopic and 17 patients with a vaginal surgical approach. Data on patients’ weight, body mass index, albumin and PG-SGA have been reported in previous publications [17, 22].

LOS and potential predictors
The median LOS for all patients in the study was 5 days (range 0-43 days). In total, 75 (48.1%) of the patients had prolonged LOS (Table 1). Patients with prolonged LOS were significantly older (mean age 62.8 years, SD 13.7) than patients with average LOS (mean age 54.5 years, SD 13.6) (p<0.01).

BMI was not significantly associated with LOS. Although fifty patients had two or more pre-existing medical co-morbidities, neither the number (Table 1), nor the specific type of co-morbidity (data not shown), were significantly different between patients with average and prolonged LOS. Low pretreatment serum albumin or hemoglobin levels, low QOL FACT-G scores and high PG-SGA scores were associated with prolonged LOS. Compared to patients with a suspicious pelvic mass, patients suspected to carry an advanced ovarian cancer were significantly more likely to have prolonged LOS (OR = 30.4; 95% CI = 3.9-236.7) (Table 1).
In the multivariable model, patients with good quality of life a diagnosis of ovarian cancer stage I or II (OR=8.13, 95% CI 1.8-36.4) or ovarian cancer stage III or IV (OR = 29.8, 95% CI 3.4-261.4) remained the only significant postsurgical factor significantly associated with prolonged LOS (Table 2).

Combining the significant predictors from the previous two models the FACT-G global score and a diagnosis of ovarian cancer remained independently statistically significant, while nutritional status and the occurrence of AEs failed to reach a significant association with prolonged LOS in this combined model (Table 3).

**Discussion**

This study assesses factors predictive for prolonged LOS (defined as >5 days or >2 days, for patients who had open abdominal or laparoscopic surgery, respectively) among gynecological cancer patients. Malnutrition and low QOL are predictors of prolonged LOS independent of patients’ age at diagnosis, surgical approach (laparoscopy or laparotomy), albumin and hemoglobin when only factors known prior to commencement of treatment are considered. Previous studies have shown that malnutrition was associated with prolonged LOS in hospitalized patients requiring treatment for various types of cancer [13, 16, 26-28]. The present manuscript is the first to confirm those findings for patients with gynecological cancer, and extends these findings even further. The present data suggest an association between pre-operative malnutrition and LOS based on both the PG-SGA global rating and the PG-SGA score. To our knowledge there is only one previous study which assessed the PG-SGA score (as opposed to the global rating) and LOS [15]. Thomas and colleagues found a
weak correlation between LOS and the PG-SGA score [15], and similar in our study the PG-SGA score was the weaker predictor compared to the global rating in multivariable analysis. However, the PG-SGA score provides dieticians with suggested appropriate intervention strategies and thus can be a clinically useful adjunct to the global rating.

Our findings show that LOS was not equally distributed between tumor types. Even after adjustment for age and surgical approach, 88% of all ovarian cancer patients had prolonged hospital stay, compared with only 59% of patients with endometrial cancer and 26% of patients with benign disease. In our previous work we described in detail that malnutrition was almost exclusively present in ovarian cancer patients compared to other gynecologic oncology diagnoses [17], which is the most likely reason why irrespective of nutritional status, ovarian cancer was so strongly associated with long LOS.

A previous study by Dean and colleagues found that gynecological cancer patients with two or more pre-existing co-morbidities had significantly longer LOS than those with one or no co-morbidities [5]. In contrast, our findings suggest that in this sample of gynecological cancer patients, neither the number of co-morbidities nor the type of co-morbidity are predictive of prolonged LOS. Further studies are required to validate these findings, carefully separating preoperative co-morbidities from postoperative complications.

In this study, we found low preoperative hemoglobin and lymphocyte counts in a small number of patients and these patients were more likely to experience prolonged LOS, but this difference was not statistically significant in adjusted modelling. Previous studies suggested that low hemoglobin levels were related to poor survival in patients with ovarian cancer [29, 30], and studies differed in their conclusions regarding the importance of age, histology, nutritional status and immune system on lymphocyte counts [31-33]. With our non-significant results, we suggest that neither of these markers are suitable factors to predict prolonged LOS.
A third biochemical marker assessed in the present study was serum albumin, generally believed to indicate the presence of chronic malnutrition. Previous studies have demonstrated an association between low serum albumin and increased postoperative complications [6, 34, 35], as well as reductions in survival in ovarian cancer patients [36]. The results of our study confirmed previous findings by Massad and colleagues in which they found an inverse correlation between serum albumin and LOS among patients with gynecological cancer [4]. However, our current results demonstrated when albumin and PG-SGA global rating [22] were assessed concurrently, the PG-SGA was a stronger predictor of LOS, and therefore more sensitive to detect malnutrition in gynecological cancer patients.

Research conducted on QOL and nutritional status in cancer patients indicates that nutritional support may lead to better QOL [11, 37, 38]. To our knowledge few investigations have examined the association between patients’ pre-treatment QOL and prolonged LOS, while concurrently assessing malnutrition. One study by Rogers and colleagues found a weak correlation between better QOL and shorter LOS in oral and oropharyngeal cancer patients [39]. In the present study we found that poor QOL prior to initial treatment was associated with prolonged LOS, and this association remained significant when adjusted for tumour stage/histology. Our results suggest that subsequent studies should assess the effect of pre-surgical nutritional interventions, or interventions aimed at improving QOL on LOS.

A limitation of our study was that data on nutritional status and QOL were only assessed before commencement of initial treatment and not at any time point afterwards. This additional information would have been of interest to identify whether changes in patients’ PG-SGA score and global rating and FACT-G score are more influential for LOS than pre-treatment score alone. In addition, given the preponderance of malnutrition among ovarian cancer patients, subsequent studies should focus on this subgroup of gynecological cancer patients. However, our study also has some major strengths, including the availability of pre-
treatment assessments for all patients, and the high participation rate among patients with
gynecological cancer.

Conclusions
In conclusion, prolonged LOS was found to be associated with low QOL and a diagnosis of
ovarian cancer, irrespective of malnutrition. Strategies to reduce LOS and improve patients’
well-being during hospital stay will need to address potentially modifiable factors, which
include QOL and malnutrition.

Competing interests
No conflicts of interest declared.

Author’s contributions
The authors' responsibilities were as follows - AO: initiated the study; BL, SK: collected data;
AO, BL, and MJ: data analysis; AO and GC: project supervision; AO, BL, SK and MJ:
writing the manuscript; and all authors: revision of the manuscript.

Acknowledgements
This research was funded by the National Health and Medical Research Committee Public
Health Fellowship NHMRC 339101 (to MJ), the Endeavour International Postgraduate
Research Scholarship (Endeavour IPRS), the University of Queensland International Living
Allowance Scholarship (UQILAS) (both to BL for this PhD project) and the Royal Brisbane
and Women’s Hospital Research Foundation (to AO).
References

1. Detsky AS, Baker JP, O'Rourke K, Goel V: Perioperative parenteral nutrition: a meta-analysis. *Ann Intern Med* 1987, **107**:195-203.

2. Santoso JT, Canada T, Latson B, Aaaadi K, Lucci JA, 3rd, Coleman RL: Prognostic nutritional index in relation to hospital stay in women with gynecologic cancer. *Obstet Gynecol* 2000, **95**:844-846.

3. Bishara S, Griffin M, Cargill A, Bali A, Gore ME, Kaye SB, Shepherd JH, Van Trappen PO: Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. *Eur J Obstet Gynecol Reprod Biol* 2007.

4. Massad LS, Vogler G, Herzog TJ, Mutch DG: Correlates of length of stay in gynecologic oncology patients undergoing inpatient surgery. *Gynecol Oncol* 1993, **51**:214-218.

5. Dean MM, Finan MA, Kline RC: Predictors of complications and hospital stay in gynecologic cancer surgery. *Obstet Gynecol* 2001, **97**:721-724.

6. Obermair A, Hagenauer S, Tamandl D, Clayton RD, Nicklin JL, Perrin LC, Ward BG, Crandon AJ: Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. *Gynecol Oncol* 2001, **83**:115-120.

7. Terada KY, Christen C, Roberts JA: Parenteral nutrition in gynecology. *J Reprod Med* 1988, **33**:957-960.

8. Burnett AF, Potkul RK, Barter JF, Barnes WA, Delgado G: Colonic surgery in gynecologic oncology. *Risk factor analysis. J Reprod Med* 1993, **38**:137-141.

9. Ottery FD: Definition of standardized nutritional assessment and interventional pathways in oncology. *Nutrition* 1996, **12**:S15-19.

10. Montazeri A, McEwen J, Gillis CR: Quality of life in patients with ovarian cancer: current state of research. *Support Care Cancer* 1996, **4**:169-179.
11. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME: **Cancer: disease and nutrition are key determinants of patients' quality of life.** *Support Care Cancer* 2004, **12**:246-252.

12. Gupta D, Lis CG, Granick J, Grutsch JF, Vashi PG, Lammersfeld CA: Malnutrition was associated with poor quality of life in colorectal cancer: a retrospective analysis. *J Clin Epidemiol* 2006, **59**:704-709.

13. Horsley P, Bauer J, Gallagher B: Poor nutritional status prior to peripheral blood stem cell transplantation is associated with increased length of hospital stay. *Bone Marrow Transplant* 2005, **35**:1113-1116.

14. Martineau J, Bauer JD, Isenring E, Cohen S: Malnutrition determined by the patient-generated subjective global assessment is associated with poor outcomes in acute stroke patients. *Clin Nutr* 2005, **24**:1073-1077.

15. Thomas JM, Isenring E, Kellett E: Nutritional status and length of stay in patients admitted to an Acute Assessment Unit. *J Hum Nutr Diet* 2007, **20**:320-328.

16. Bauer J, Capra S, Ferguson M: Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. *Eur J Clin Nutr* 2002, **56**:779-785.

17. Laky B, Janda M, Bauer J, Vavra C, Cleghorn G, Obermair A: **Malnutrition among gynaecological cancer patients.** *Eur J Clin Nutr* 2007, **61**:642-646.

18. Laky B, Janda M, Cleghorn G, Obermair A: Comparison of different nutritional assessments and body-composition measurements in detecting malnutrition among gynecologic cancer patients. *Am J Clin Nutr* 2008, **87**:1678-1685.

19. Cella DF: **Quality of life: concepts and definition.** *J Pain Symptom Manage* 1994, **9**:186-192.
20. Gil KM, Gibbons HE, Jenison EL, Hopkins MP, von Gruenigen VE: Baseline characteristics influencing quality of life in women undergoing gynecologic oncology surgery. *Health Qual Life Outcomes* 2007, 5:25.

21. von Gruenigen VE, Frasure HE, Jenison EL, Hopkins MP, Gil KM: Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. *Gynecol Oncol* 2006, 103:120-126.

22. Laky B, Janda M, Cleghorn G, Obermair A: Comparison of different nutritional assessments and body composition measurements to detect malnutrition among gynaecological cancer patients. *Am J Clin Nutr* 2008, 87:000-000 In Press (accepted 14th March, 2008).

23. Ottery FD: Patient-Generated Subjective Global Assessment. In *The Clinical Guide to Oncology Nutrition*. Edited by McCallum PD, Polisena CG. Chicago: The American Dietetic Association; 2000: 11-23

24. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al.: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. *J Clin Oncol* 1993, 11:570-579.

25. Cella D, Hahn EA, Dineen K: Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. *Qual Life Res* 2002, 11:207-221.

26. Baker JP, Detsky AS, Wesson DE, Wolman SL, Stewart S, Whitewell J, Langer B, Jeejeebhoy KN: Nutritional assessment: a comparison of clinical judgement and objective measurements. *N Engl J Med* 1982, 306:969-972.

27. Planas M, Audivert S, Perez-Portabella C, Burgos R, Puiggros C, Casanelles JM, Rossello J: Nutritional status among adult patients admitted to an university-affiliated hospital in Spain at the time of genoma. *Clin Nutr* 2004, 23:1016-1024.
28. Pichard C, Kyle UG, Morabia A, Perrier A, Vermeulen B, Unger P: Nutritional assessment: lean body mass depletion at hospital admission is associated with an increased length of stay. *Am J Clin Nutr* 2004, 79:613-618.

29. Obermair A, Handisurya A, Kaider A, Sevelda P, Kolbl H, Gitsch G: The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. *Cancer* 1998, 83:726-731.

30. Obermair A, Petru E, Windbichler G, Peters-Engl C, Graf AH, Stummvoll W, Kaider A, Kurschel S, Kolbl H, Sevelda P: **Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer.** *Oncol Rep* 2000, 7:639-644.

31. Izaks GJ, Remarque EJ, Becker SV, Westendorp RG: **Lymphocyte count and mortality risk in older persons.** *The Leiden 85-Plus Study. J Am Geriatr Soc* 2003, 51:1461-1465.

32. Kuzuya M, Kanda S, Koike T, Suzuki Y, Iguchi A: Lack of correlation between total lymphocyte count and nutritional status in the elderly. *Clin Nutr* 2005, 24:427-432.

33. van Bokhorst-de van der Schueren MA, van Leeuwen PA, Sauerwein HP, Kuik DJ, Snow GB, Quak JJ: **Assessment of malnutrition parameters in head and neck cancer and their relation to postoperative complications.** *Head Neck* 1997, 19:419-425.

34. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF: Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. *Arch Surg* 1999, 134:36-42.

35. Alphs HH, Zahurak ML, Bristow RE, Diaz-Montes TP: Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. *Gynecol Oncol* 2006, 103:1048-1053.
36. Parker D, Bradley C, Bogle SM, Lay J, Masood M, Hancock AK, Naylor B, Price JJ: Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. *Br J Obstet Gynaecol* 1994, **101**:888-893.

37. Small W, Carrara R, Danford L, Logemann JA, Cella D: Quality of life and nutrition in the patient with cancer. *Integrating Nutrition into your Cancer Program* 2002.

38. Marin Caro MM, Laviano A, Pichard C: Impact of nutrition on quality of life during cancer. *Curr Opin Clin Nutr Metab Care* 2007, **10**:480-487.

39. Rogers SN, Lowe D, Brown JS, Vaughan ED: The relationship between length of stay and health-related quality of life in patients treated by primary surgery for oral and oropharyngeal cancer. *Int J Oral Maxillofac Surg* 2001, **30**:209-215.
| Table 1: Pre-surgery factors associated with prolonged LOS |
|--------------------------------------------------------|
|                                                     |
| % (n) with prolonged LOS | Univariate model | OR | 95% CI | P | Multivariable model | OR | 95% CI | P |
| Total | 157 | 48.1 (75) | | | | | | |
| **Body mass index** | | | | | | | | |
| Underweight (<18.5) | 3 | 66.7 (2) | 2.96 | 0.12 - 70.3 | 0.50 | Reference group | | |
| Normal (18.5-24.99) | 39 | 46.2 (18) | | | | | | |
| Overweight (25.0-29.99) | 47 | 44.7 (21) | 0.91 | 0.36 - 2.30 | 0.84 | Reference group | | |
| Obese (≥30) | 67 | 50.7 (34) | 1.31 | 0.55 - 3.16 | 0.54 | Reference group | | |
| **Pre-existing co-morbidity** | | | | | | | | |
| No or 1 co-morbidity | 107 | 45.8 (49) | | | | | | |
| 2 or more co-morbidities | 50 | 54.0 (27) | 0.12 | 0.56 - 2.75 | 0.59 | Reference group | | |
| **Blood** | | | | | | | | |
| Albumin | | | | | | | | |
| Average (>35g/L) | 124 | 41.9 (52) | | | | | Reference group | | |
| Below Average (≤35g/L) | 22 | 86.4 (19) | 8.81 | 1.82 - 42.6 | 0.007 | 0.86 | 0.12 - 6.5 | 0.88 |
| Hemoglobin | | | | | | | | |
| Average (>120g/L) | 117 | 42.7 (50) | | | | | Reference group | | |
| Below Average (≤120g/L) | 36 | 69.4 (25) | 3.21 | 1.31 - 7.68 | 0.01 | 2.11 | 0.65 - 6.86 | 0.21 |
| Lymphocytes | | | | | | | | |
| Average (1.5-4.0x10⁹/L) | 109 | 44.0 (48) | | | | | Reference group | | |
| Below Average (≤1.5x10⁹/L) | 44 | 64.4 (27) | 1.46 | 0.66 - 3.22 | 0.35 | Reference group | | |
| **FACT-G global score** | | | | | | | | |
| 157 | [75.3 ± 16.9] | 0.95 | 0.93 - 0.98 | <0.001 | 0.96 | 0.93 - 0.99 | 0.007 |
| **Nutritional assessment** | | | | | | | | |
| PG-SGA score | 157 | [9.5 ± 6.6] | 1.13 | 1.05 - 1.22 | 0.001 | 0.94 | 0.84 - 1.06 | 0.33 |
| PG-SGA A | 118 | 39.3 (44) | | | | | Reference group | | |
| PG-SGA B and C | 39 | 82.1 (32) | 6.89 | 2.48 - 19.2 | <0.001 | 5.28 | 0.98 - 28.5 | 0.05 |
Table 1 continued

| Histology and Stage | N   | % (n) with prolonged LOS | Univariate model ¹ | Multivariable model ² | P   | OR   | 95% CI   | P   | OR   | 95% CI   | P   |
|---------------------|-----|--------------------------|--------------------|-----------------------|-----|------|----------|-----|------|----------|-----|
|                     |     |                          | Reference group    |                       |     |      |          |     |      |          |     |
| Benign/LMP/ OvCa stage I or II ¹ | 81  | 42.0 (34)                | 42.0               | 3.9-236.7             | 0.001 | 14.7 | 1.61-134.7 | 0.02 |
| OvCa stage III or IV       | 23  | 95.7 (22)                | 95.7               | 0.63-3.04             | 0.42 | 1.71 | 0.67-4.34 | 0.002 |
| Endometrial cancer        | 36  | 50.0 (18)                | 50.0               | 0.04-0.86             | 0.03 | 0.10 | 0.01-0.71 | 0.02 |
| Cervical cancer           | 22  | 11.8 (2)                 | 11.8               | 0.04-0.86             | 0.03 | 0.10 | 0.01-0.71 | 0.02 |

¹adjusted for age and surgical approach; ² Multivariable model including albumin, FACT-G score, PG-SGA score and PG-SGA global rating; adjusted for age and surgical approach; ³ Continuous variables: mean ± standard deviation for group with average LOS; ⁴Continuous variables: mean ± standard deviation for group with prolonged LOS ;

*Abbreviations:* LOS, Length of hospital stay; OR, Odds Ratio; CI, Confidence interval; PG-SGA, Patient-Generated Subjective Global Assessment; FACT-G, Functional Assessment of Cancer Therapy-General.
